SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4g34'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XDK_B_9CRB600_1 (RETINOIC ACID RECEPTOR, BETA)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	ALA A 923 LEU A1009 ILE A1070 ILE A1071 LEU A 937	None	1.09A	1xdkB-4g34A: undetectable	1xdkB-4g34A: 22.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2AOT_B_2PMB401_1 (HISTAMINE N-METHYLTRANSFERASE)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	PHE A1020 TYR A1018 PHE A1038 TYR A 989 GLU A1015	None	1.40A	2aotB-4g34A: 0.0	2aotB-4g34A: 19.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_D_MIXD3539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	7 / 12	LEU A 598 GLY A 599 GLY A 601 VAL A 606 LYS A 938 ASN A 941 ASP A 954	924 A1101 ( 4.1A) None None 924 A1101 ( 4.8A) None None 924 A1101 (-3.7A)	1.06A	2fumD-4g34A: 23.4	2fumD-4g34A: 27.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HC4_A_VDXA525_2 (VITAMIN D RECEPTOR)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 7	LEU A1016 LEU A1013 ILE A1006 ARG A1064	None	1.23A	2hc4A-4g34A: undetectable	2hc4A-4g34A: 23.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_A_STIA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 6	LEU A 598 LYS A 621 VAL A 651 ILE A 885	924 A1101 ( 4.1A) None 924 A1101 (-4.6A) 924 A1101 ( 4.6A)	0.42A	2hyyA-4g34A: 20.6	2hyyA-4g34A: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_B_STIB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 6	LEU A 598 LYS A 621 VAL A 651 ILE A 885	924 A1101 ( 4.1A) None 924 A1101 (-4.6A) 924 A1101 ( 4.6A)	0.54A	2hyyB-4g34A: 20.6	2hyyB-4g34A: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2V0M_D_KLND1498_1 (CYTOCHROME P450 3A4)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 11	LEU A1013 ILE A1070 ALA A 921 GLU A 993 LEU A 937	None	1.29A	2v0mD-4g34A: undetectable	2v0mD-4g34A: 22.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 10	LEU A 598 VAL A 606 LYS A 621 VAL A 651 ILE A 885 VAL A 952	924 A1101 ( 4.1A) 924 A1101 ( 4.8A) None 924 A1101 (-4.6A) 924 A1101 ( 4.6A) None	0.76A	3cs9A-4g34A: 21.0	3cs9A-4g34A: 27.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 9	LEU A 598 VAL A 606 LYS A 621 VAL A 651 ILE A 885 VAL A 952	924 A1101 ( 4.1A) 924 A1101 ( 4.8A) None 924 A1101 (-4.6A) 924 A1101 ( 4.6A) None	0.77A	3cs9B-4g34A: 21.4	3cs9B-4g34A: 27.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 9	LEU A 598 VAL A 606 LYS A 621 VAL A 651 ILE A 885 VAL A 952	924 A1101 ( 4.1A) 924 A1101 ( 4.8A) None 924 A1101 (-4.6A) 924 A1101 ( 4.6A) None	0.75A	3cs9C-4g34A: 20.9	3cs9C-4g34A: 27.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K5V_A_STIA2_2 (TYROSINE-PROTEIN KINASE ABL1)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 6	LEU A 598 LYS A 621 VAL A 651 ILE A 885	924 A1101 ( 4.1A) None 924 A1101 (-4.6A) 924 A1101 ( 4.6A)	0.50A	3k5vA-4g34A: 16.5	3k5vA-4g34A: 26.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K5V_B_STIB2_2 (TYROSINE-PROTEIN KINASE ABL1)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 6	LEU A 598 LYS A 621 VAL A 651 ILE A 885	924 A1101 ( 4.1A) None 924 A1101 (-4.6A) 924 A1101 ( 4.6A)	0.48A	3k5vB-4g34A: 18.8	3k5vB-4g34A: 26.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3LXK_A_MI1A1125_1 (TYROSINE-PROTEIN KINASE JAK3)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	7 / 12	LEU A 598 GLY A 599 VAL A 606 ALA A 619 LYS A 621 VAL A 651 ASP A 954	924 A1101 ( 4.1A) None 924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 (-4.6A) 924 A1101 (-3.7A)	0.67A	3lxkA-4g34A: 22.3	3lxkA-4g34A: 25.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MDT_B_VORB506_1 (CHOLESTEROL 24-HYDROXYLASE)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 11	LEU A 927 PHE A 926 SER A 929 ILE A 650 ALA A 641	None	1.14A	3mdtB-4g34A: undetectable	3mdtB-4g34A: 22.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 6	VAL A 606 LYS A 621 VAL A 651 ILE A 885	924 A1101 ( 4.8A) None 924 A1101 (-4.6A) 924 A1101 ( 4.6A)	0.39A	3mssD-4g34A: 20.3	3mssD-4g34A: 26.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 CYH A 890 PHE A 943 PHE A 955 GLY A 956	924 A1101 ( 4.8A) 924 A1101 (-3.5A) 924 A1101 (-3.9A) 924 A1101 ( 4.2A) 924 A1101 ( 4.4A) None	0.84A	3og7A-4g34A: 23.6	3og7A-4g34A: 27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 LYS A 621 CYH A 890 PHE A 955 GLY A 956	924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 (-3.9A) 924 A1101 ( 4.4A) None	0.79A	3og7A-4g34A: 23.6	3og7A-4g34A: 27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OG7_A_032A1_1 (AKAP9-BRAF FUSION PROTEIN)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 LYS A 621 LEU A 642 CYH A 890 PHE A 955 GLY A 956	924 A1101 ( 4.8A) None 924 A1101 (-3.9A) 924 A1101 (-3.9A) 924 A1101 ( 4.4A) None	0.75A	3og7A-4g34A: 23.6	3og7A-4g34A: 27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IK6_B_LURB201_1 (TRANSTHYRETIN)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 8	MET A 887 LEU A 883 ALA A 656 LEU A 658	924 A1101 (-3.7A) None None None	0.82A	4ik6B-4g34A: undetectable	4ik6B-4g34A: 18.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0W_A_ADNA501_1 (AURORA KINASE A)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 6	LEU A 598 GLY A 599 VAL A 606 ALA A 619	924 A1101 ( 4.1A) None 924 A1101 ( 4.8A) 924 A1101 (-3.5A)	0.26A	4o0wA-4g34A: 24.3	4o0wA-4g34A: 26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QOP_D_HQED503_1 (CATALASE)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 9	ILE A 620 PRO A 594 GLN A 886 TYR A 618 ASP A 614	None	1.47A	4qopD-4g34A: 0.0	4qopD-4g34A: 20.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 CYH A 890 PHE A 943 GLY A 953 PHE A 955	924 A1101 ( 4.8A) 924 A1101 (-3.5A) 924 A1101 (-3.9A) 924 A1101 ( 4.2A) 924 A1101 (-4.6A) 924 A1101 ( 4.4A)	0.99A	4rzvB-4g34A: 23.3	4rzvB-4g34A: 28.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 CYH A 890 PHE A 943 PHE A 955 GLY A 956	924 A1101 ( 4.8A) 924 A1101 (-3.5A) 924 A1101 (-3.9A) 924 A1101 ( 4.2A) 924 A1101 ( 4.4A) None	0.80A	4rzvB-4g34A: 23.3	4rzvB-4g34A: 28.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RZV_B_032B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 LYS A 621 CYH A 890 PHE A 955 GLY A 956	924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 (-3.9A) 924 A1101 ( 4.4A) None	0.73A	4rzvB-4g34A: 23.3	4rzvB-4g34A: 28.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TYJ_A_0LIA801_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 6	LEU A 598 VAL A 606 LYS A 621 ILE A 650	924 A1101 ( 4.1A) 924 A1101 ( 4.8A) None None	0.49A	4tyjA-4g34A: 21.6	4tyjA-4g34A: 24.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 CYH A 890 PHE A 943 GLY A 953 PHE A 955	924 A1101 ( 4.8A) 924 A1101 (-3.5A) 924 A1101 (-3.9A) 924 A1101 ( 4.2A) 924 A1101 (-4.6A) 924 A1101 ( 4.4A)	0.78A	4xv2A-4g34A: 23.6	4xv2A-4g34A: 27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 LYS A 621 CYH A 890 GLY A 953 PHE A 955	924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 (-3.9A) 924 A1101 (-4.6A) 924 A1101 ( 4.4A)	0.92A	4xv2A-4g34A: 23.6	4xv2A-4g34A: 27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 CYH A 890 PHE A 943 GLY A 953 ASP A 954 PHE A 955	924 A1101 ( 4.8A) 924 A1101 (-3.9A) 924 A1101 ( 4.2A) 924 A1101 (-4.6A) 924 A1101 (-3.7A) 924 A1101 ( 4.4A)	1.43A	4xv2A-4g34A: 23.6	4xv2A-4g34A: 27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4YNM_A_SAMA2304_0 (HISTONE-LYSINE N-METHYLTRANSFERASE ASH1L)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	LYS A 930 GLY A 931 HIS A 934 HIS A 647 ILE A 650	None	1.49A	4ynmA-4g34A: undetectable	4ynmA-4g34A: 19.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4YPA_C_SAMC2304_0 (HISTONE-LYSINE N-METHYLTRANSFERASE ASH1L)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	LYS A 930 GLY A 931 HIS A 934 HIS A 647 ILE A 650	None	1.45A	4ypaC-4g34A: undetectable	4ypaC-4g34A: 19.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 CYH A 890 PHE A 943 GLY A 953 PHE A 955	924 A1101 ( 4.8A) 924 A1101 (-3.5A) 924 A1101 (-3.9A) 924 A1101 ( 4.2A) 924 A1101 (-4.6A) 924 A1101 ( 4.4A)	0.77A	5cswA-4g34A: 23.3	5cswA-4g34A: 28.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	VAL A 606 ALA A 619 LYS A 621 CYH A 890 PHE A 955	924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 (-3.9A) 924 A1101 ( 4.4A)	0.73A	5cswA-4g34A: 23.3	5cswA-4g34A: 28.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 CYH A 890 PHE A 943 GLY A 953 PHE A 955	924 A1101 ( 4.8A) 924 A1101 (-3.5A) 924 A1101 (-3.9A) 924 A1101 ( 4.2A) 924 A1101 (-4.6A) 924 A1101 ( 4.4A)	0.74A	5cswB-4g34A: 23.3	5cswB-4g34A: 28.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 LYS A 621 CYH A 890 GLY A 953 PHE A 955	924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 (-3.9A) 924 A1101 (-4.6A) 924 A1101 ( 4.4A)	0.92A	5cswB-4g34A: 23.3	5cswB-4g34A: 28.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	VAL A 606 LEU A 642 CYH A 890 PHE A 943 PHE A 955	924 A1101 ( 4.8A) 924 A1101 (-3.9A) 924 A1101 (-3.9A) 924 A1101 ( 4.2A) 924 A1101 ( 4.4A)	0.88A	5cswB-4g34A: 23.3	5cswB-4g34A: 28.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5GTR_A_ESTA601_1 (ESTROGEN RECEPTOR)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	LEU A1016 LEU A1017 MET A1052 GLY A1010 LEU A1009	None	0.95A	5gtrA-4g34A: undetectable	5gtrA-4g34A: 20.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	VAL A 606 ALA A 619 LYS A 621 ILE A 885 PHE A 955 GLY A 956	924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 ( 4.6A) 924 A1101 ( 4.4A) None	0.81A	5hesB-4g34A: 22.6	5hesB-4g34A: 27.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	VAL A 606 ALA A 619 ILE A 885 PHE A 943 GLY A 953	924 A1101 ( 4.8A) 924 A1101 (-3.5A) 924 A1101 ( 4.6A) 924 A1101 ( 4.2A) 924 A1101 (-4.6A)	0.49A	5hieA-4g34A: 3.8	5hieA-4g34A: 28.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	VAL A 606 ALA A 619 LYS A 621 ILE A 885 GLY A 953	924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 ( 4.6A) 924 A1101 (-4.6A)	0.75A	5hieA-4g34A: 3.8	5hieA-4g34A: 28.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	VAL A 606 ALA A 619 ILE A 885 PHE A 943 GLY A 953	924 A1101 ( 4.8A) 924 A1101 (-3.5A) 924 A1101 ( 4.6A) 924 A1101 ( 4.2A) 924 A1101 (-4.6A)	0.49A	5hieB-4g34A: 22.1	5hieB-4g34A: 28.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	VAL A 606 ALA A 619 LYS A 621 ILE A 885 GLY A 953	924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 ( 4.6A) 924 A1101 (-4.6A)	0.74A	5hieB-4g34A: 22.1	5hieB-4g34A: 28.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	VAL A 606 ALA A 619 ILE A 885 PHE A 943 GLY A 953	924 A1101 ( 4.8A) 924 A1101 (-3.5A) 924 A1101 ( 4.6A) 924 A1101 ( 4.2A) 924 A1101 (-4.6A)	0.49A	5hieD-4g34A: 22.4	5hieD-4g34A: 28.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 12	VAL A 606 ALA A 619 LYS A 621 ILE A 885 GLY A 953	924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 ( 4.6A) 924 A1101 (-4.6A)	0.75A	5hieD-4g34A: 22.4	5hieD-4g34A: 28.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I6X_A_8PRA705_1 (SODIUM-DEPENDENT SEROTONIN TRANSPORTER)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 10	ASP A1005 ILE A1070 PHE A 917 SER A1008 GLY A1010	None	1.22A	5i6xA-4g34A: undetectable	5i6xA-4g34A: 19.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IZJ_F_AZ1F2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAR-DAR-DAR)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 7	GLY A 599 GLY A 601 GLY A 604 VAL A 606	None None None 924 A1101 ( 4.8A)	0.34A	5izjB-4g34A: 21.7	5izjB-4g34A: 24.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5VCY_A_DB8A401_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	6 / 12	LEU A 598 VAL A 606 ALA A 619 LYS A 621 CYH A 890 PHE A 943	924 A1101 ( 4.1A) 924 A1101 ( 4.8A) 924 A1101 (-3.5A) None 924 A1101 (-3.9A) 924 A1101 ( 4.2A)	0.36A	5vcyA-4g34A: 23.4	5vcyA-4g34A: 30.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5W5V_A_ANWA701_0 (SERINE/THREONINE-PRO TEIN KINASE TBK1)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	5 / 9	LEU A 598 ALA A 619 VAL A 651 MET A 887 CYH A 890	924 A1101 ( 4.1A) 924 A1101 (-3.5A) 924 A1101 (-4.6A) 924 A1101 (-3.7A) 924 A1101 (-3.9A)	0.61A	5w5vA-4g34A: 15.1	5w5vA-4g34A: 21.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6FGC_A_ACTA811_0 (GEPHYRIN)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	3 / 3	LEU A1017 LEU A 914 ARG A 910	None	0.63A	6fgcA-4g34A: undetectable	6fgcA-4g34A: 20.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6FGD_A_ACTA810_0 (GEPHYRIN)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	3 / 3	LEU A1017 LEU A 914 ARG A 910	None	0.63A	6fgdA-4g34A: undetectable	6fgdA-4g34A: 20.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6G2P_A_TRPA502_0 (FLAVIN-DEPENDENT L-TRYPTOPHAN OXIDASE VIOA)	4g34	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Homo sapiens)	4 / 7	ARG A1026 TYR A 989 LEU A1057 VAL A1033	None	1.35A	6g2pA-4g34A: undetectable	6g2pA-4g34A: 23.89

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1XDK_B_9CRB600_1","RETINOIC ACID RECEPTOR, BETA","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"ALA A 923;LEU A1009;ILE A1070;ILE A1071;LEU A 937","None","1.09A","1xdkB-4g34A:undetectable","1xdkB-4g34A:22.35"],["2AOT_B_2PMB401_1","HISTAMINE N-METHYLTRANSFERASE","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"PHE A1020;TYR A1018;PHE A1038;TYR A 989;GLU A1015","None","1.40A","2aotB-4g34A:0.0","2aotB-4g34A:19.58"],["2FUM_D_MIXD3539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",7,"LEU A 598;GLY A 599;GLY A 601;VAL A 606;LYS A 938;ASN A 941;ASP A 954","924 A1101 ( 4.1A);None;None;924 A1101 ( 4.8A);None;None;924 A1101 (-3.7A)","1.06A","2fumD-4g34A:23.4","2fumD-4g34A:27.81"],["2HC4_A_VDXA525_2","VITAMIN D RECEPTOR","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"LEU A1016;LEU A1013;ILE A1006;ARG A1064","None","1.23A","2hc4A-4g34A:undetectable","2hc4A-4g34A:23.96"],["2HYY_A_STIA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"LEU A 598;LYS A 621;VAL A 651;ILE A 885","924 A1101 ( 4.1A);None;924 A1101 (-4.6A);924 A1101 ( 4.6A)","0.42A","2hyyA-4g34A:20.6","2hyyA-4g34A:27.27"],["2HYY_B_STIB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"LEU A 598;LYS A 621;VAL A 651;ILE A 885","924 A1101 ( 4.1A);None;924 A1101 (-4.6A);924 A1101 ( 4.6A)","0.54A","2hyyB-4g34A:20.6","2hyyB-4g34A:27.27"],["2V0M_D_KLND1498_1","CYTOCHROME P450 3A4","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"LEU A1013;ILE A1070;ALA A 921;GLU A 993;LEU A 937","None","1.29A","2v0mD-4g34A:undetectable","2v0mD-4g34A:22.11"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"LEU A 598;VAL A 606;LYS A 621;VAL A 651;ILE A 885;VAL A 952","924 A1101 ( 4.1A);924 A1101 ( 4.8A);None;924 A1101 (-4.6A);924 A1101 ( 4.6A);None","0.76A","3cs9A-4g34A:21.0","3cs9A-4g34A:27.24"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"LEU A 598;VAL A 606;LYS A 621;VAL A 651;ILE A 885;VAL A 952","924 A1101 ( 4.1A);924 A1101 ( 4.8A);None;924 A1101 (-4.6A);924 A1101 ( 4.6A);None","0.77A","3cs9B-4g34A:21.4","3cs9B-4g34A:27.24"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"LEU A 598;VAL A 606;LYS A 621;VAL A 651;ILE A 885;VAL A 952","924 A1101 ( 4.1A);924 A1101 ( 4.8A);None;924 A1101 (-4.6A);924 A1101 ( 4.6A);None","0.75A","3cs9C-4g34A:20.9","3cs9C-4g34A:27.24"],["3K5V_A_STIA2_2","TYROSINE-PROTEIN KINASE ABL1","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"LEU A 598;LYS A 621;VAL A 651;ILE A 885","924 A1101 ( 4.1A);None;924 A1101 (-4.6A);924 A1101 ( 4.6A)","0.50A","3k5vA-4g34A:16.5","3k5vA-4g34A:26.91"],["3K5V_B_STIB2_2","TYROSINE-PROTEIN KINASE ABL1","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"LEU A 598;LYS A 621;VAL A 651;ILE A 885","924 A1101 ( 4.1A);None;924 A1101 (-4.6A);924 A1101 ( 4.6A)","0.48A","3k5vB-4g34A:18.8","3k5vB-4g34A:26.91"],["3LXK_A_MI1A1125_1","TYROSINE-PROTEIN KINASE JAK3","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",7,"LEU A 598;GLY A 599;VAL A 606;ALA A 619;LYS A 621;VAL A 651;ASP A 954","924 A1101 ( 4.1A);None;924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 (-4.6A);924 A1101 (-3.7A)","0.67A","3lxkA-4g34A:22.3","3lxkA-4g34A:25.90"],["3MDT_B_VORB506_1","CHOLESTEROL 24-HYDROXYLASE","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"LEU A 927;PHE A 926;SER A 929;ILE A 650;ALA A 641","None","1.14A","3mdtB-4g34A:undetectable","3mdtB-4g34A:22.89"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"VAL A 606;LYS A 621;VAL A 651;ILE A 885","924 A1101 ( 4.8A);None;924 A1101 (-4.6A);924 A1101 ( 4.6A)","0.39A","3mssD-4g34A:20.3","3mssD-4g34A:26.91"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;CYH A 890;PHE A 943;PHE A 955;GLY A 956","924 A1101 ( 4.8A);924 A1101 (-3.5A);924 A1101 (-3.9A);924 A1101 ( 4.2A);924 A1101 ( 4.4A);None","0.84A","3og7A-4g34A:23.6","3og7A-4g34A:27.30"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;LYS A 621;CYH A 890;PHE A 955;GLY A 956","924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 (-3.9A);924 A1101 ( 4.4A);None","0.79A","3og7A-4g34A:23.6","3og7A-4g34A:27.30"],["3OG7_A_032A1_1","AKAP9-BRAF FUSION PROTEIN","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;LYS A 621;LEU A 642;CYH A 890;PHE A 955;GLY A 956","924 A1101 ( 4.8A);None;924 A1101 (-3.9A);924 A1101 (-3.9A);924 A1101 ( 4.4A);None","0.75A","3og7A-4g34A:23.6","3og7A-4g34A:27.30"],["4IK6_B_LURB201_1","TRANSTHYRETIN","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"MET A 887;LEU A 883;ALA A 656;LEU A 658","924 A1101 (-3.7A);None;None;None","0.82A","4ik6B-4g34A:undetectable","4ik6B-4g34A:18.93"],["4O0W_A_ADNA501_1","AURORA KINASE A","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"LEU A 598;GLY A 599;VAL A 606;ALA A 619","924 A1101 ( 4.1A);None;924 A1101 ( 4.8A);924 A1101 (-3.5A)","0.26A","4o0wA-4g34A:24.3","4o0wA-4g34A:26.98"],["4QOP_D_HQED503_1","CATALASE","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"ILE A 620;PRO A 594;GLN A 886;TYR A 618;ASP A 614","None","1.47A","4qopD-4g34A:0.0","4qopD-4g34A:20.28"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;CYH A 890;PHE A 943;GLY A 953;PHE A 955","924 A1101 ( 4.8A);924 A1101 (-3.5A);924 A1101 (-3.9A);924 A1101 ( 4.2A);924 A1101 (-4.6A);924 A1101 ( 4.4A)","0.99A","4rzvB-4g34A:23.3","4rzvB-4g34A:28.08"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;CYH A 890;PHE A 943;PHE A 955;GLY A 956","924 A1101 ( 4.8A);924 A1101 (-3.5A);924 A1101 (-3.9A);924 A1101 ( 4.2A);924 A1101 ( 4.4A);None","0.80A","4rzvB-4g34A:23.3","4rzvB-4g34A:28.08"],["4RZV_B_032B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;LYS A 621;CYH A 890;PHE A 955;GLY A 956","924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 (-3.9A);924 A1101 ( 4.4A);None","0.73A","4rzvB-4g34A:23.3","4rzvB-4g34A:28.08"],["4TYJ_A_0LIA801_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"LEU A 598;VAL A 606;LYS A 621;ILE A 650","924 A1101 ( 4.1A);924 A1101 ( 4.8A);None;None","0.49A","4tyjA-4g34A:21.6","4tyjA-4g34A:24.40"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;CYH A 890;PHE A 943;GLY A 953;PHE A 955","924 A1101 ( 4.8A);924 A1101 (-3.5A);924 A1101 (-3.9A);924 A1101 ( 4.2A);924 A1101 (-4.6A);924 A1101 ( 4.4A)","0.78A","4xv2A-4g34A:23.6","4xv2A-4g34A:27.66"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;LYS A 621;CYH A 890;GLY A 953;PHE A 955","924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 (-3.9A);924 A1101 (-4.6A);924 A1101 ( 4.4A)","0.92A","4xv2A-4g34A:23.6","4xv2A-4g34A:27.66"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;CYH A 890;PHE A 943;GLY A 953;ASP A 954;PHE A 955","924 A1101 ( 4.8A);924 A1101 (-3.9A);924 A1101 ( 4.2A);924 A1101 (-4.6A);924 A1101 (-3.7A);924 A1101 ( 4.4A)","1.43A","4xv2A-4g34A:23.6","4xv2A-4g34A:27.66"],["4YNM_A_SAMA2304_0","HISTONE-LYSINE N-METHYLTRANSFERASE ASH1L","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"LYS A 930;GLY A 931;HIS A 934;HIS A 647;ILE A 650","None","1.49A","4ynmA-4g34A:undetectable","4ynmA-4g34A:19.63"],["4YPA_C_SAMC2304_0","HISTONE-LYSINE N-METHYLTRANSFERASE ASH1L","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"LYS A 930;GLY A 931;HIS A 934;HIS A 647;ILE A 650","None","1.45A","4ypaC-4g34A:undetectable","4ypaC-4g34A:19.63"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;CYH A 890;PHE A 943;GLY A 953;PHE A 955","924 A1101 ( 4.8A);924 A1101 (-3.5A);924 A1101 (-3.9A);924 A1101 ( 4.2A);924 A1101 (-4.6A);924 A1101 ( 4.4A)","0.77A","5cswA-4g34A:23.3","5cswA-4g34A:28.30"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"VAL A 606;ALA A 619;LYS A 621;CYH A 890;PHE A 955","924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 (-3.9A);924 A1101 ( 4.4A)","0.73A","5cswA-4g34A:23.3","5cswA-4g34A:28.30"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;CYH A 890;PHE A 943;GLY A 953;PHE A 955","924 A1101 ( 4.8A);924 A1101 (-3.5A);924 A1101 (-3.9A);924 A1101 ( 4.2A);924 A1101 (-4.6A);924 A1101 ( 4.4A)","0.74A","5cswB-4g34A:23.3","5cswB-4g34A:28.30"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;LYS A 621;CYH A 890;GLY A 953;PHE A 955","924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 (-3.9A);924 A1101 (-4.6A);924 A1101 ( 4.4A)","0.92A","5cswB-4g34A:23.3","5cswB-4g34A:28.30"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"VAL A 606;LEU A 642;CYH A 890;PHE A 943;PHE A 955","924 A1101 ( 4.8A);924 A1101 (-3.9A);924 A1101 (-3.9A);924 A1101 ( 4.2A);924 A1101 ( 4.4A)","0.88A","5cswB-4g34A:23.3","5cswB-4g34A:28.30"],["5GTR_A_ESTA601_1","ESTROGEN RECEPTOR","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"LEU A1016;LEU A1017;MET A1052;GLY A1010;LEU A1009","None","0.95A","5gtrA-4g34A:undetectable","5gtrA-4g34A:20.66"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"VAL A 606;ALA A 619;LYS A 621;ILE A 885;PHE A 955;GLY A 956","924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 ( 4.6A);924 A1101 ( 4.4A);None","0.81A","5hesB-4g34A:22.6","5hesB-4g34A:27.79"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"VAL A 606;ALA A 619;ILE A 885;PHE A 943;GLY A 953","924 A1101 ( 4.8A);924 A1101 (-3.5A);924 A1101 ( 4.6A);924 A1101 ( 4.2A);924 A1101 (-4.6A)","0.49A","5hieA-4g34A:3.8","5hieA-4g34A:28.49"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"VAL A 606;ALA A 619;LYS A 621;ILE A 885;GLY A 953","924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 ( 4.6A);924 A1101 (-4.6A)","0.75A","5hieA-4g34A:3.8","5hieA-4g34A:28.49"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"VAL A 606;ALA A 619;ILE A 885;PHE A 943;GLY A 953","924 A1101 ( 4.8A);924 A1101 (-3.5A);924 A1101 ( 4.6A);924 A1101 ( 4.2A);924 A1101 (-4.6A)","0.49A","5hieB-4g34A:22.1","5hieB-4g34A:28.49"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"VAL A 606;ALA A 619;LYS A 621;ILE A 885;GLY A 953","924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 ( 4.6A);924 A1101 (-4.6A)","0.74A","5hieB-4g34A:22.1","5hieB-4g34A:28.49"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"VAL A 606;ALA A 619;ILE A 885;PHE A 943;GLY A 953","924 A1101 ( 4.8A);924 A1101 (-3.5A);924 A1101 ( 4.6A);924 A1101 ( 4.2A);924 A1101 (-4.6A)","0.49A","5hieD-4g34A:22.4","5hieD-4g34A:28.49"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"VAL A 606;ALA A 619;LYS A 621;ILE A 885;GLY A 953","924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 ( 4.6A);924 A1101 (-4.6A)","0.75A","5hieD-4g34A:22.4","5hieD-4g34A:28.49"],["5I6X_A_8PRA705_1","SODIUM-DEPENDENT SEROTONIN TRANSPORTER","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"ASP A1005;ILE A1070;PHE A 917;SER A1008;GLY A1010","None","1.22A","5i6xA-4g34A:undetectable","5i6xA-4g34A:19.96"],["5IZJ_F_AZ1F2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAR-DAR-DAR","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"GLY A 599;GLY A 601;GLY A 604;VAL A 606","None;None;None;924 A1101 ( 4.8A)","0.34A","5izjB-4g34A:21.7","5izjB-4g34A:24.21"],["5VCY_A_DB8A401_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",6,"LEU A 598;VAL A 606;ALA A 619;LYS A 621;CYH A 890;PHE A 943","924 A1101 ( 4.1A);924 A1101 ( 4.8A);924 A1101 (-3.5A);None;924 A1101 (-3.9A);924 A1101 ( 4.2A)","0.36A","5vcyA-4g34A:23.4","5vcyA-4g34A:30.37"],["5W5V_A_ANWA701_0","SERINE\/THREONINE-PROTEIN KINASE TBK1","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",5,"LEU A 598;ALA A 619;VAL A 651;MET A 887;CYH A 890","924 A1101 ( 4.1A);924 A1101 (-3.5A);924 A1101 (-4.6A);924 A1101 (-3.7A);924 A1101 (-3.9A)","0.61A","5w5vA-4g34A:15.1","5w5vA-4g34A:21.25"],["6FGC_A_ACTA811_0","GEPHYRIN","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",3,"LEU A1017;LEU A 914;ARG A 910","None","0.63A","6fgcA-4g34A:undetectable","6fgcA-4g34A:20.98"],["6FGD_A_ACTA810_0","GEPHYRIN","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",3,"LEU A1017;LEU A 914;ARG A 910","None","0.63A","6fgdA-4g34A:undetectable","6fgdA-4g34A:20.98"],["6G2P_A_TRPA502_0","FLAVIN-DEPENDENT L-TRYPTOPHAN OXIDASE VIOA","4g34","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","Homo sapiens",4,"ARG A1026;TYR A 989;LEU A1057;VAL A1033","None","1.35A","6g2pA-4g34A:undetectable","6g2pA-4g34A:23.89"]]